DISQVER® at the annual meeting of the DGHO in Vienna: Application of NGS-based diagnostics in Haematooncology and Medical Oncology
Infections and bloodstream infections are a major cause of complications in the therapy of oncological and hematological patients. But how can the pathogens that lead to these infections be detected quickly and reliably? From 7 to 9 October, the Noscendo team will...
Noscendo presents DISQVER® at HAI 2022, the 24th Capital Congress of the DGAI for Anaesthesiology and Intensive Care Therapy
After a pandemic-related break, the 24th Capital Congress of the German Society for Anaesthesiology & Intensive Care Medicine (DGAI) will be held again this year in presence. From September 14-17, the focus will be on medical advances in anaesthesia, intensive...
Next-Generation Sequencing-Based Decision Support for Intensivists in Difficult-to-Diagnose Disease States
Software driven NGS-based diagnostics company Noscendo secures funding to revolutionize the diagnosis of infectious diseases
Series B led by a renowned family office focused on life sciences, with impact-focused VC Revent as co-investor, plus support from existing investorsFurther development of proprietary DISQVER® technology and international expansion Duisburg, May 16, 2022 –...
Sepsis, commonly known as blood poisoning, is the most severe form of an infectious disease which causes over 75 000 deaths annually in Germany. Early, reliable pathogen identification is pivotal with regard to the course of the disease. However, this is often not...
Improved patient outcomes with fewer dialysis cases thanks to more precise diagnosis – Health insurance companies also see savings potential
Fortschritte in der Infektionsdiagnostik: Die Noscendo GmbH bietet mit ihrem DISQVER-Diagnoseverfahren die Möglichkeit, Infektionserreger im Rahmen einer Krankenhausbehandlung schneller und präziser zu bestimmen als bisher möglich. Das nutzt nicht nur Patientinnen und Patienten. Auch Krankenkassen sehen darin Einsparpotenziale, etwa wenn teure Folgebehandlungen wie Dialysen vermieden werden können.
Noscendo GmbH, a leading diagnostic company for identification and assessment of bloodstream associated pathogens and other infections announced today the addition of Heiner Dreismann, former President and CEO of Roche Molecular Systems, to its Board of Directors
Noscendo is committed to supporting physicians, clinics and laboratories in their daily work in the field of pathogen detection and to provide therapy-relevant results that directly benefit patients. With its groundbreaking diagnostic platform DISQVER®, Noscendo helps save patients' lives through highly accurate pathogen detection.
Next-Generation Sequencing-Based Decision Support for Intensivists in Difficult-to-Diagnose Disease States: A Case Report of Invasive Cerebral Aspergillosis
Aspergillus spp. are widespread environmental pathogens that can induce invasive aspergillosis, especially in immunocompromised patients.
Fast identification of disseminated mucormycosis in hematooncologic patients by next-generation sequencing: a case series.
Invasive mucormycoses are increasingly emerging and a severe health threat with potentially fatal outcome especially for immunocompromised patients. They are challenging to diagnose: the diagnostic workup includes numerous tests, is time-intensive and frequently invasive. Cultivation is difficult and slow and yet frequently remains negative. Fast diagnosis for a timely treatment is urgently needed. We here describe a case series, where untargeted next-generation sequencing (NGS, with Noscendo’s CE-IVD marked DISQVER® pathogen test) provided identification of moulds in three patients with underlying hematologic malignancies from a standard blood draw within 24h after sample arrival.
Pathogen detection by metagenomic next-generation sequencing during neutropenic fever in patients with haematological malignancies
Febrile neutropenia (FN) following chemotherapy is a major cause of morbidity requiring urgent use of broad-spectrum antibiotics. Blood culture (BC) is a standard diagnostic method for FN but sensitivity of pathogen detection is low. Timely identification of causative pathogens using metagenomic next-generation sequencing (mNGS) of circulating cell-free DNA (cfDNA) from plasma could reduce morbidity and costs by enabling early-targeted antimicrobial therapy. The aim of this study is to establish mNGS (DISQVER) for the detection of pathogens within 24h in immunocompromised haematological patients with FN
SensID and Noscendo combine forces to develop a contamination-free reference material with known human DNA quantity and virus status for clinical system validation. The reference material is developed by SensID and tested by Noscendo to be positive for standard microbial DNA and completely free of contaminating microbial DNA. The reference materials will serve as process controls to ensure highest process quality and validity for patient samples.
Immune-Response Patterns and Next Generation Sequencing Diagnostics for the Detection of Mycoses in Patients with Septic Shock—Results of a Combined Clinical and Experimental Investigation
Int. J. Mol. Sci. 2017 August. doi: 10.3390/ijms18081796
In hospitals in Germany, infections are one of the greatest challenges. So-called sepsis, colloquially also known as blood poisoning, accounts for a major portion of these infections. According to a study by Jena University Hospital, nationwide 320,000 people develop sepsis, and one quarter of those affected die of the sequelae. This analysis implies that in the state of Rhineland-Palatinate almost 16,000 people will fall ill with sepsis each year. The faster and the more effectively the responsible germs can be fought, the faster the patient will recover. This also means that life-saving intensive care beds become available again more quickly, which is of major importance during the current corona pandemic. “Thanks to a new contract of Mainz University Medical Centre with software company Noscendo and TK health insurance, a new software-based method comprising a special test and a pathogen platform can now be used to identify the causative pathogens. This means that it is possible to help those insured with us more quickly and more effectively,” rejoices Jörn Simon, director of TK’s state office in Rhineland-Palatinate
“Rapid results cure patients and relieve pressure on hospitals” – Noscendo’s Lab featured by BioRegioStern
Noscendo GmbH arrives at TTR in Reutlingen with innovative diagnostics platform Rapid results cure patients and relieve pressure on hospitals (Stuttgart/Reutlingen) – Noscendo GmbH recently opened a branch at the Reutlingen site of the Tübingen-Reutlingen Technology Park (TTR). Its state-of-the-art development and application laboratory identifies the causes of numerous infectious diseases exceptionally fast using next-generation sequencing (NGS) based on the company’s own diagnostics platform, which reliably detects bacteria, DNA viruses, fungi and parasites in patients’ blood samples. In intensive care medicine, obtaining…
Noscendo closes series A financing and launches DISQVER® in Europe to significantly improve diagnosis of infectious diseases
Noscendo GmbH, a diagnostics company dedicated to the identification and assessment of bloodstream-associated pathogens and other infections, today announced the commencement of operations in its own development and application laboratory as well as the closing of a financing round. Renowned new investors including Earlybird, Paua Ventures and the JIH Family Office joined the round while existing investors, such as Wieland Capital and High-Tech Gründerfonds, continued to invest.
J MOL DIAGN 2020 March. doi: https://doi.org/10.1016/j.jmoldx.2019.12.006 Learn...
Noscendo expands proprietary diagnostic platform DISQVER® to include microbial resistances in partnership with University Hospital Bonn
Noscendo GmbH and the University Hospital Bonn (UKB) today announced the successful signing of a cooperative agreement with the Institute for Hygiene and Public Health (IHPH) at the UKB, working towards expansion of the proprietary and CE-certified diagnostic platform DISQVER® in the field of microbial resistances. Through the partnership, Noscendo GmbH will fully molecularly characterise up to 8000 antibiotic-resistant pathogens from over 35 species using the latest sequencing technology. The institute’s strain bank, which has been running for 20 years and is continually growing, and the environmental databank are fed from various national and international projects and their structure addresses significant resistance problems of today’s inpatient treatments.
Noscendo reaches CE certification as key milestone for its proprietary diagnostic platform DISQVER® and conducts successful piloting in eight maximum care hospitals
Noscendo GmbH today announced the successful completion of the development of its proprietary diagnostic platform DISQVER® combined with corresponding CE certification as the first key milestone since the seed financing in October 2018. Noscendo’s platform detects bacteria, fungi, DNA viruses and parasites in the patient’s bloodstream on the basis of next-generation sequencing (NGS) and uses proprietary algorithms to assess the corresponding pathogen relevance
Enhanced Performance of Next-Generation Sequencing Diagnostics Compared With Standard of Care Microbiological Diagnostics in Patients Suffering From Septic Shock
Crit. Care Med. 2019 May. doi: 10.1097/CCM.0000000000003658
New approaches for the detection of invasive fungal diseases in patients following liver transplantation—results of an observational clinical pilot study
Langenbecks Arch. Surg. 2019 May. doi: 10.1007/s00423-019-01769-y
Noscendo closes Financing Round for CE Certification and Market Entry Preparation of Platform Diagnostics for Bloodstream Associated Infections
In two-thirds of all cases, existing diagnostic procedures do not allow intensive care clinicians to draw conclusions on the pathogens causing bloodstream associated infections such as sepsis (“blood poisoning”) and endocarditis (inflammation of the inner layers of the heart). Therapy options are therefore very often limited to administering broad-band antibiotics. Unspecific therapy leads to high mortality rates and severe complications in many patients, and also accentuates the issue of resistant hospital pathogens.
Next-generation sequencing diagnostics of bacteremia in sepsis (Next GeneSiS-Trial): Study protocol of a prospective, observational, noninterventional, multicenter, clinical trial
Medicine (Baltimore) 2018 February. doi: 10.1097/MD.0000000000009868
JGenome Med. 2016 Dezember. doi: 10.1186/s13073-016-0326-8